« Back           Text Size   +  -     Links       Sitemap       RSS       Glossary
Member area access button
Roadmap of Priorities: AIMS
> The Informed Patient
> Fighting Counterfeiting
> Coding & Identification
> Patients W.A.I.T. Indicator
> EU Pharmaceutical Package
> Innovative Medicines Initiative
> Intellectual Property Rights
> Parallel trade
> Global Public Health
Printable version Print button
Home > Roadmap of Priorities: AIMS > The Informed Patient

Health information for Europe’s citizens.

EU institutions, healthcare stakeholders and EU citizens seem to agree since many years that communication with patients and the general public on health issues and prescription medicines should be improved with the objective of having better informed patients. Information can contribute to prevention, early diagnosis, better treatment of disease as well as improved adherence. Enhanced access for all citizens to non-promotional, high-quality health information and greater participation of well-informed patients in decisions affecting their health will therefore lead to healthier societies around Europe.

However, a European solution to this existing European challenge remains outstanding. Therefore, EFPIA calls on policy-makers to improve access for all European patients and citizens to high-quality health and medicines information in their own language. Many Europeans are still disadvantaged in accessing information they need. Together with other respected partners, the pharmaceutical industry can play an essential role in the provision of high-quality health information.


EFPIA’s general position regarding the provision of non-promotional information on prescription medicines:

  • European citizens expect and deserve a modern and comprehensive EU information strategy that will truly benefit them and help to improve public health.

  • Access for all EU citizens and patients to non-promotional health and medicines information in their language must be improved. EFPIA does not consider Direct-to-Consumer Advertising as an appropriate model for Europe.

  • Access to high quality medicines information from multiple sources is needed, including from the pharmaceutical industry, respecting the highest quality standards. Information should be judged by its actual quality, not the source providing it.

  • Availability of, and access to high-quality medicines information in all languages via the internet must be enhanced, while recognising the need for non-electronic tools for parts of the population and for improving access to such tools.

  • Public Private Partnerships, involving a range of healthcare stakeholders, could be one part of a comprehensive strategy.

  • Legislative reform at EU level is needed with the primary goal of giving the same opportunities to all EU citizens, taking into account positive experiences gained at individual Member State level.

  • Self-regulatory schemes with efficient governance and enforcement procedures (including third party involvement) would be the most practical and beneficial way forward, provided that an adequate legislative frame is put in place allowing the provision of high quality information from multiple sources. This approach would help ensuring that information to patients on prevention, diagnosis, treatment and management of diseases meets the highest quality standards and provides the greatest benefits to patients.

EFPIA Position Papers:

Press Releases:

                                                                                                  Further Press releases available here...

EFPIA Key Messages:

Contributions:

EFPIA Guidelines:

Documents & Links



The Public Health Portal of the European Union

Logo_PharmaceuticalForum
Logo EBE Making for Mank
EFPIA©1999-2010 - All rights reserved - Last update: 06 September 2010 - Best viewed with Flash6 - Optimal Screen Resolution: 1024x768